References
1.Conway A, McCarthy AL, Lawrence P, et al: The prevention,
detection and management of cancer treatment-induced cardiotoxicity: a
meta-review. BMC Cancer, 2015. 15 : p. 366.
2.Lenneman CG,Sawyer DB: Cardio-Oncology: An Update on
Cardiotoxicity of Cancer-Related Treatment. Circ Res, 2016.118 (6): p. 1008-20.
3.Vasanthakumar A, Kattusamy K,Prasad R: Regulation of
daunorubicin biosynthesis in Streptomyces peucetius - feed forward and
feedback transcriptional control. J Basic Microbiol, 2013.53 (8): p. 636-44.
4.Narezkina A,Nasim K: Anthracycline Cardiotoxicity. Circ Heart
Fail, 2019. 12 (3): p. e005910.
5.Barry E, Alvarez JA, Scully RE, et al: Anthracycline-induced
cardiotoxicity: course, pathophysiology, prevention and management.Expert Opin Pharmacother, 2007. 8 (8): p. 1039-58.
6.Edwardson DW, Narendrula R, Chewchuk S, et al: Role of Drug
Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines.Curr Drug Metab, 2015. 16 (6): p. 412-26.
7.Zagar TM, Cardinale DM,Marks LB: Breast cancer
therapy-associated cardiovascular disease. Nat Rev Clin Oncol, 2016.13 (3): p. 172-84.
8.Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al: 2016 ESC
Position Paper on cancer treatments and cardiovascular toxicity
developed under the auspices of the ESC Committee for Practice
Guidelines: The Task Force for cancer treatments and cardiovascular
toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail,
2017. 19 (1): p. 9-42.
9.Santoro C, Arpino G, Esposito R, et al: 2D and 3D strain for
detection of subclinical anthracycline cardiotoxicity in breast cancer
patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging,
2017. 18 (8): p. 930-936.
10.Mondillo S, Galderisi M, Mele D, et al: Speckle-tracking
echocardiography: a new technique for assessing myocardial function. J
Ultrasound Med, 2011. 30 (1): p. 71-83.
11.Smiseth OA, Torp H, Opdahl A, et al: Myocardial strain imaging:
how useful is it in clinical decision making? Eur Heart J, 2016.37 (15): p. 1196-207.
12.Motoki H, Borowski AG, Shrestha K, et al: Incremental
prognostic value of assessing left ventricular myocardial mechanics in
patients with chronic systolic heart failure. J Am Coll Cardiol, 2012.60 (20): p. 2074-81.
13.Plana JC, Galderisi M, Barac A, et al: Expert consensus for
multimodality imaging evaluation of adult patients during and after
cancer therapy: a report from the American Society of Echocardiography
and the European Association of Cardiovascular Imaging. Eur Heart J
Cardiovasc Imaging, 2014. 15 (10): p. 1063-93.
14.Curigliano G, Cardinale D, Suter T, et al: Cardiovascular
toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO
Clinical Practice Guidelines. Ann Oncol, 2012. 23 Suppl 7 : p.
vii155-66.
15.Negishi K, Negishi T, Hare JL, et al: Independent and
incremental value of deformation indices for prediction of
trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr, 2013.26 (5): p. 493-8.
16.Nagueh SF, Appleton CP, Gillebert TC, et al: Recommendations
for the evaluation of left ventricular diastolic function by
echocardiography. Eur J Echocardiogr, 2009. 10 (2): p. 165-93.
17.Harjai KJ, Scott L, Vivekananthan K, et al: The Tei index: a
new prognostic index for patients with symptomatic heart failure. J Am
Soc Echocardiogr, 2002. 15 (9): p. 864-8.
18.Lang RM, Bierig M, Devereux RB, et al: Recommendations for
chamber quantification: a report from the American Society of
Echocardiography’s Guidelines and Standards Committee and the Chamber
Quantification Writing Group, developed in conjunction with the European
Association of Echocardiography, a branch of the European Society of
Cardiology. J Am Soc Echocardiogr, 2005. 18 (12): p. 1440-63.
19.Seo Y, Ishizu T, Atsumi A, et al: Three-dimensional speckle
tracking echocardiography. Circ J, 2014. 78 (6): p. 1290-301.
20.Galderisi M, Nistri S, Mondillo S, et al: Methodological
approach for the assessment of ultrasound reproducibility of cardiac
structure and function: a proposal of the study group of
Echocardiography of the Italian Society of Cardiology (Ultra Cardia SIC)
part I. Cardiovasc Ultrasound, 2011. 9 : p. 26.
21.Yang AQ, Zhang Y, Xu MJ, et al: Use of echocardiography to
monitor myocardial damage during anthracycline chemotherapy.Echocardiography-a Journal of Cardiovascular Ultrasound and Allied
Techniques, 2019. 36 (3): p. 495-502.
22.Slordal L,Spigset O: Heart failure induced by non-cardiac
drugs. Drug Saf, 2006. 29 (7): p. 567-86.
23.Ewer MS,Ewer SM: Long-term cardiac safety of dose-dense
anthracycline therapy cannot be predicted from early ejection fraction
data. J Clin Oncol, 2009. 27 (36): p. 6073-5.
24.Tarantini L, Cioffi G, Gori S, et al: Trastuzumab adjuvant
chemotherapy and cardiotoxicity in real-world women with breast cancer.J Card Fail, 2012. 18 (2): p. 113-9.
25.Hoffmann R, Barletta G, von Bardeleben S, et al: Analysis of
left ventricular volumes and function: a multicenter comparison of
cardiac magnetic resonance imaging, cine ventriculography, and
unenhanced and contrast-enhanced two-dimensional and three-dimensional
echocardiography. J Am Soc Echocardiogr, 2014. 27 (3): p.
292-301.
26.Thavendiranathan P,Amir E: Left Ventricular Dysfunction With
Trastuzumab Therapy: Is Primary Prevention the Best Option? J Clin
Oncol, 2017. 35 (8): p. 820-825.
27.Theodoulou M,Seidman AD: Cardiac effects of adjuvant therapy
for early breast cancer. Semin Oncol, 2003. 30 (6): p. 730-9.
28.Crosby J, Amundsen BH, Hergum T, et al: 3-D speckle tracking
for assessment of regional left ventricular function. Ultrasound Med
Biol, 2009. 35 (3): p. 458-71.
29.Cerqueira MD, Weissman NJ, Dilsizian V, et al: Standardized
myocardial segmentation and nomenclature for tomographic imaging of the
heart. A statement for healthcare professionals from the Cardiac Imaging
Committee of the Council on Clinical Cardiology of the American Heart
Association. Circulation, 2002. 105 (4): p. 539-42.
Figure 1 : Real-time 3D full volume data obtained by 4D
Automated LV Quantification software(4D Auto LVQ software, GE
Healthcare).(A4C: Apical four-chamber; A2C:Apical two-chamber; A3C:
Apical three-chamber; PSAX: Parasternal short-axis)